NCT Number: NCT00387946
Efficacy and Safety of Dianicline Treatment as an Aid to Smoking Cessation in Cigarette Smokers (AMERIDIAN)
The primary study objective is to demonstrate the efficacy of dianicline as an aid to smoking cessation in cigarette smokers. The main secondary objectives are to assess the: craving for cigarettes, nicotine withdrawal symptoms, and safety of dianicline.
Looking for future studies?
Notify MeKey information
Age range
18 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 3
Primary location
Administrative Office, Laval, Quebec, Canada
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Outpatients, over legal age, smoking at least 10 cigarettes/day as a mean within the 2 months preceding the screening visit.
Exclusion criteria
- Patients who have taken an investigational drug within the past six months prior to the screening visit.
- Patients who had a previous quit attempt (= or >1 day with the aid of pharmacological adjunct) in the previous three months (before screening).
- Patients who have smoked or consumed non-tobacco cigarettes or any form of tobacco product (other than cigarettes such as cigars, pipes, smokeless tobacco, etc) more than 3 times within the 3 months preceding the screening visit.
- Patients who currently present with (based on Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition [DSM-IV]):
- Psychotic disorder
- Major depressive episode
- Pregnant or breast-feeding women.
- Women of childbearing potential not protected by effective contraceptive method of birth control and/or who are unwilling or unable to be tested for pregnancy. Medically acceptable methods of birth control for this study include approved hormonal contraceptive medications or devices, approved intra-uterine contraceptive devices, use of two combined barrier methods.
- Patients who have suffered from a myocardial infarction, unstable angina or other major cardiovascular event within the past week prior to screening.
- Patients who have a history of multiple allergic reactions to medications in two drug classes.
- Patients who have QTcF > 500 ms on the electrocardiogram (ECG).
- Patients with mild, moderate or severe renal impairment.
- Patients who have an abnormal laboratory test of potential clinical significance at screening.
Treatment and study plan
Primary outcomes
-
To assess the continuous abstinence from tobacco smoking at every visit during the last 4 weeks of treatment period, i.e. from week 4 to week 7, through direct inquiry of patients, exhaled carbon monoxide (CO) testing, and plasma cotinine measurements
Secondary outcomes
-
Questionnaire of Smoking Urges to assess craving for cigarettes; Hughes and Hatsukami Minnesota Withdrawal Scale to measure nicotine withdrawal, number of smoke-free days, and average number of cigarettes smoked from smoking status interview
Sponsors and collaborators
Lead sponsor
Sanofi
Industry
Registry information
Official study title
An International, Seven-week, Double-blind, Placebo-controlled, Two Parallel Group Study to Assess the Efficacy of Dianicline 40 mg Bid as an Aid to Smoking Cessation in Cigarette Smokers
Important dates
- Study start
- 2006
- Primary completion
- 2007
- Study completion
- 2007
- First posted
- Oct 13, 2006
- Registry last updated
- Feb 17, 2012
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Implementation Science to Reduce the Disparity in Tobacco Treatment Among Individuals With Serious Mental Illness
NCT05952401
Behavior, Chemically-Induced Disorders
St Louis, Missouri, United States
View Trial DetailsA Facebook Intervention for Young Sexual and Gender Minority Smokers
NCT03259360
Behavior, Chemically-Induced Disorders
San Francisco, California, United States
View Trial DetailsHelping Poor Smokers Quit
NCT03194958
Behavior, Behavior, Addictive
St Louis, Missouri, United States
View Trial DetailsConnecting Alaska Native People to Quit Smoking
NCT03645941
Behavior, Cigarette Smoking
Rochester, Minnesota, United States
View Trial Details